Trending Stock News

Tyme Technologies, Inc. (TYME) Reaches $3.70 After 3.00% Up Move; 8 Bullish Analysts Covering Fate Therapeutics, Inc. (FATE)

Among 10 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Fate Therapeutics had 22 analyst reports since October 6, 2015 according to SRatingsIntel. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Outperform” rating by Wedbush on Tuesday, November 8. Leerink Swann initiated Fate Therapeutics, Inc. (NASDAQ:FATE) on Friday, September 8 with “Buy” rating. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Buy” rating given on Tuesday, March 6 by Piper Jaffray. The rating was maintained by H.C. Wainwright on Tuesday, March 20 with “Hold”. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Outperform” rating given on Tuesday, March 6 by BMO Capital Markets. Piper Jaffray maintained it with “Buy” rating and $20.0 target in Thursday, March 15 report. The stock has “Outperform” rating by Wedbush on Tuesday, March 6. The firm earned “Buy” rating on Friday, April 6 by Wells Fargo. The company was maintained on Wednesday, November 1 by BMO Capital Markets. The stock has “Neutral” rating by H.C. Wainwright on Tuesday, March 6. See Fate Therapeutics, Inc. (NASDAQ:FATE) latest ratings:

16/05/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0000 Maintain
06/04/2018 Broker: Wells Fargo Rating: Buy New Target: $18.0000 Maintain
29/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $12.0000 Maintain
20/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $12.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
06/03/2018 Broker: Raymond James Rating: Hold Downgrade
06/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
06/03/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $7 New Target: $20 Maintain
06/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral New Target: $12 Downgrade
06/03/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $10 New Target: $19 Maintain

The stock of Tyme Technologies, Inc. (NASDAQ:TYME) is a huge mover today! The stock increased 7.25% or $0.25 during the last trading session, reaching $3.7. About 104,930 shares traded. Tyme Technologies, Inc. (NASDAQ:TYME) has risen 3.14% since June 19, 2017 and is uptrending. It has underperformed by 9.43% the S&P500. Some Historical TYME News: ; 09/04/2018 – TYME TECHNOLOGIES INC – AS OF MARCH 31, 2018, HAD APPROXIMATELY $29.0 MLN IN CASH AND CASH EQUIVALENTS; 27/03/2018 – TYME ANNOUNCES FIRST SITE OPEN FOR ITS PHASE Il TRIAL WITH SM-88 IN PANCREATIC CANCER; 14/03/2018 – FDA Acceptance of IND for Tyme to Begin Phase Il Trial in Pancreatic Cancer; 06/04/2018 – Tyme and JAF Announce Sarcoma Treatment Collaboration; 09/04/2018 – Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018; 17/05/2018 – Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting; 22/04/2018 – DJ Tyme Technologies Inc, Inst Holders, 1Q 2018 (TYME); 09/04/2018 – Tyme Provides Clinical and Corporate Update for Fiscal Yr End 2018; 29/03/2018 – Tyme Technologies, Inc. Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, M; 08/03/2018 Tyme Technologies Announces Closing of Public Offering of Common StkThe move comes after 5 months positive chart setup for the $374.54 million company. It was reported on Jun, 19 by Barchart.com. We have $3.81 PT which if reached, will make NASDAQ:TYME worth $11.24 million more.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. The company has market cap of $374.54 million. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. It currently has negative earnings.

More notable recent Tyme Technologies, Inc. (NASDAQ:TYME) news were published by: Nasdaq.com which released: “Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs” on June 12, 2018, also Nasdaq.com with their article: “Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors” published on May 30, 2018, Streetinsider.com published: “Tyme Inc. (TYME) Reports Detailed Data & Analyses with SM-88 on First Human Study & Compassionate Use Programs” on June 12, 2018. More interesting news about Tyme Technologies, Inc. (NASDAQ:TYME) were released by: Benzinga.com and their article: “42 Biggest Movers From Yesterday” published on June 13, 2018 as well as Benzinga.com‘s news article titled: “41 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: June 12, 2018.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $611.57 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

Investors sentiment increased to 2.08 in 2018 Q1. Its up 0.50, from 1.58 in 2017Q4. It increased, as 9 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 23 funds opened positions while 31 raised stakes. 36.46 million shares or 12.96% more from 32.27 million shares in 2017Q4 were reported. Geode Mgmt Ltd Com stated it has 404,634 shares. Manufacturers Life Ins The reported 0% stake. Dimensional Fund L P owns 23,500 shares. Franklin Resource Inc reported 5.85 million shares. Meeder Asset holds 0% in Fate Therapeutics, Inc. (NASDAQ:FATE) or 1,134 shares. Price T Rowe Associate Md owns 962,773 shares or 0% of their US portfolio. Northern, Illinois-based fund reported 496,919 shares. Moreover, Tiaa Cref Ltd Limited Liability Company has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE). First Manhattan Co accumulated 100 shares. State Street reported 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Moreover, Atlantic Grp Ltd Limited Liability Company has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 2,000 shares. State Common Retirement Fund, New York-based fund reported 40,500 shares. Federated Investors Pa accumulated 101 shares. Acadian Asset Mgmt Limited Co owns 10,347 shares or 0% of their US portfolio. Eam Investors Lc invested in 279,161 shares.

The stock increased 1.22% or $0.14 during the last trading session, reaching $11.57. About 188,769 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 233.04% since June 19, 2017 and is uptrending. It has outperformed by 220.47% the S&P500. Some Historical FATE News: ; 16/05/2018 – FATE THERAPEUTICS, MEMORIAL SLOAN KETTERING EXPAND LICENSE PACT; 23/04/2018 – DJ Fate Therapeutics Inc, Inst Holders, 1Q 2018 (FATE); 16/04/2018 – Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Prog; 06/03/2018 – FATE THERAPEUTICS INC FATE.O : WEDBUSH RAISES TARGET PRICE TO $19 FROM $10; 05/03/2018 – FATE THERAPEUTICS INC QTRLY SHR LOSS $0.29; 03/05/2018 – Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results; 06/03/2018 – FATE THERAPEUTICS INC FATE.O : BMO RAISES TARGET PRICE TO $20 FROM $7; 29/03/2018 – Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018; 19/03/2018 – FATE THERAPEUTICS REPORTS NO EVENTS OF CANCER RELAPSE; 06/03/2018 – FATE THERAPEUTICS INC FATE.O : H. C. WAINWRIGHT RAISES TARGET PRICE TO $12

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *